Clinical efficacy of colquhounia root tablets in patients with moderate atopic dermatitis

WANG Wenwen; DONG Yao; ZHAO Lu; REN Luning; DU Hongyang

doi:10.11958/20252619

Abstract：Objective To explore the influence of colquhounia root tablets on the clinical efficacy and inflammatory indicators in patients with moderate atopic dermatitis(AD).Methods A total of 80 patients with moderate AD were prospectively included in this study.Patients were randomly divided into the control group and the test group,with 40 patients in each group.Ultimately,33 patients in the control group and 32 in the test group were completed the study.The control group received oral hydroxyzine hydrochloride tablets and cetirizine hydrochloride capsules,and externally applied mometasone furoate cream and polymyxin B compound ointment.The test group received the same treatment along with oral Colquhounia root tablets(4 tablets per dose,3 doses per day).All patients underwent 8 weeks of treatment.Clinical response rates were evaluated in both groups.Before and after treatment,peripheral blood samples were taken to measure and calculate the neutrophil/lymphocyte ratio(NLR),eosinophil/lymphocyte ratio(ELR),monocyte/lymphocyte ratio(MLR),platelet/lymphocyte ratio(PLR)and serum total immunoglobulin E(IgE)levels.Additionally,eczema area and severity index(EASI),pruritus numeric rating scale(PP-NRS),investigator global assessment(IGA)and SCORAD scores were recorded.Results The clinical response rate was significantly higher in the test group than that of the control group(68.8%vs.39.4%,P=0.033).After treatment,the NLR and IgE levels were significantly lower in the test group than those of the control group(P<0.05).Furthermore,the reduction in clinical scores(EASI,IGA,SCORAD)were more significant in the test group compared to those of the control group(P<0.05).There was no significant difference in the incidence of adverse reaction events between the two groups during the treatment period(6.06%vs.9.38%,χ²=0.251,P=0.672).Conclusion Colquhounia root tablets show significant efficacy in treating moderate atopic dermatitis by improving clinical symptoms and reducing inflammatory markers,and have a relatively high overall safety.